Evidence map›Paper›PMID 41921085›Full record

ArticleJMIR public health and surveillance2026

Projected Health and Economic Benefits of Air Quality Targets in China: Modeling Study.

Siyuan Wang, Zhiwei Xu, Gian Luca Di Tanna, Yawen Jiang, Mingsheng Chen, Laura Downey, Stephen Jan, Lei Si

Abstract read
In one paragraph

Article in JMIR public health and surveillance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siyuan WangThe George Institute for Global Health, UNSW, Sydney, New South Wales, Australia.ORCID 0009-0009-5870-870X
Zhiwei XuSchool of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia.ORCID 0000-0001-7903-2141
Gian Luca Di TannaDepartment of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland.ORCID 0000-0002-5470-3567
Yawen JiangSchool of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, China.ORCID 0000-0002-0498-0662
Mingsheng ChenSchool of Health Policy and Management, Nanjing Medical University, No. 101 Longmian Avenue, Nanjing, 211166, China, 86 02586868506.ORCID 0009-0006-4970-9856
Laura DowneyThe George Institute for Global Health, UNSW, Sydney, New South Wales, Australia.ORCID 0000-0002-9563-7113
Stephen JanThe George Institute for Global Health, UNSW, Sydney, New South Wales, Australia.ORCID 0000-0003-2839-1405
Lei SiSchool of Health Sciences, Faculty of Health, Western Sydney University, Campbelltown, New South Wales, Australia.ORCID 0000-0002-3044-170X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Air pollution continues to impose a substantial health and economic burden in China. Despite recent improvements, national annual average PM2.5 (fine particulate matter) concentrations remain substantially above the levels deemed safe by the World Health Organization (WHO), underscoring the need for more stringent air quality control. Objective: This study aims to quantify the projected health and economic benefits of reducing PM2.5 concentrations in China under the Healthy China 2030 plan. Methods: Using the 2020 ground-level PM2.5 data as a baseline, we projected cause-specific mortality and morbidity outcomes for 337 prefecture-level cities in China from 2020 to 2030 under four policy scenarios: (1) Healthy China 2030 (10% reduction by 2025; 25 µg/m³ by 2030) and the WHO targets of (2) 15 µg/m³, (3) 10 µg/m³, and (4) 5 µg/m³ by 2030. Mortality for noncommunicable diseases, lower respiratory infections, stroke, ischemic heart disease, lung cancer, and chronic obstructive pulmonary disease was estimated using the Global Exposure Mortality Model. Hospitalizations were modeled using log-linear models based on national evidence. Results: In 2020, PM2.5 concentrations across the 337 cities ranged from 7 to 63 µg/m³, with a national annual mean of 32.6 µg/m³. Higher concentration levels were observed in eastern China, particularly in the eastern and southeastern regions. Overall, our analysis accounted for nearly 70% of the total population of China in 2020. Our analysis shows that maintaining PM2.5 at 2020 levels was projected to result in 9.04 million (95% CI 7.70-10.67 million) attributable deaths, compared with 8.63 million (95% CI 7.42-10.30 million) under the policy scenario, corresponding to 0.41 million premature deaths averted under the 14th Five-Year Clean Air Plan. Over 2021-2030, PM2.5-attributable deaths declined from 17.76 million (95% CI 14.21-20.95 million) under baseline conditions to 15.96 million (95% CI 12.85-19.15 million) under the policy scenario. Achieving WHO targets would further reduce attributable deaths to 13.99 million (95% CI 11.25-15.25 million) at 15 µg/m³, 12.86 million (95% CI 10.85-14.85 million) at 10 µg/m³, and 11.49 million (95% CI 8.96-13.45 million) at 5 µg/m³. The annual average hospitalizations declined by 21,422 cardiovascular and 26,545 respiratory admissions under the policy scenario, increasing to 41,690 and 51,681 at 15 µg/m³, 51,884 and 64,333 at 10 µg/m³, and 62,146 and 77,073 at 5 µg/m³, respectively. Subsequently, total economic gains reached US $123.7 billion under the policy scenario and increased to US $185.7 billion, US $240.7 billion, and US $306.5 billion under the 15, 10, and 5 µg/m³ scenarios, respectively. Conclusions: Our findings suggest that while the Healthy China 2030 Plan offered substantial health gains, achieving stricter WHO air quality targets could yield 2-3 times greater benefits. These findings will support the future development of stricter evidence-based national air quality standards.

Indexed as

Air PollutionCost-Benefit AnalysisChinaEnvironmental ExposureForecastingHumansParticulate MatterParticulate Matterair pollutionChinaeconomic benefitshealth impact modelingparticulate matter

Identifiers

PMID41921085
PMCPMC13043006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.